Horizon Shares Slide Premarket on Report That FTC to Fight Amgen Deal
16 Maio 2023 - 07:29AM
Dow Jones News
By Colin Kellaher
Horizon Therapeutics tumbled in premarket trading Tuesday
following a published report that U.S. regulators will move to
block the $27.8 billion acquisition of the drugmaker by Amgen.
Bloomberg, citing a person familiar with the matter, late Monday
reported that the Federal Trade Commission is expected to file a
lawsuit Tuesday to block the deal on the grounds it would hamper
innovation and slow the pace of drug development.
Amgen in December said it would pay $116.50 a share in cash for
Horizon, marking the largest healthcare merger announced in
2022.
Amgen said it wasn't aware of any FTC decision on the deal,
while Horizon deferred comment to Amgen, according to the Bloomberg
report.
Horizon shares, which closed Monday at $112.25, were recently
down nearly 17% at $93.49 in premarket trading, while Amgen shares
edged up 0.6% to $235.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
May 16, 2023 06:14 ET (10:14 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Amgen (NASDAQ:AMGN)
Gráfico Histórico do Ativo
De Fev 2024 até Mar 2024
Amgen (NASDAQ:AMGN)
Gráfico Histórico do Ativo
De Mar 2023 até Mar 2024